Researchers at MUSC Hollings Cancer Center have identified a promising new weapon in the fight against head and neck cancers. The preclinical drug attacks cancer cells from within by damaging their mitochondria, the cells’ energy factories.
Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
The landscape of cancer treatment is rapidly evolving. Increasingly, there is recognition that care must go beyond treating the disease itself—it must also address the whole person and the debilitating symptoms patients experience during and after treatment.
As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.
Nearly five decades ago, I joined City of Hope’s nascent bone marrow transplant (BMT) program, which focused on improving outcomes for patients with advanced leukemia.
Chaired by the University of Miami Sylvester Comprehensive Cancer Center, the 24th Cancer Centers Informatics Society (Ci4CC) Symposium will convene the nation’s leading designated and community cancer centers with a central focus on advancing precision oncology.
The fight against lung cancer is evolving, with groundbreaking research shedding light on the intricate interplay between biology, environment, and health disparities.
City of Hope has developed and deployed HopeLLM, a proprietary generative AI platform that addresses critical operational challenges in hospitals while advancing personalized cancer care.
